To Search for Sober Housing Click Here

Understanding GLP-1s and Alcohol Use Disorder

Woman with GLP-1 in her hands

Addiction counselors and behavioral health clinicians have been  paying close attention to a new trend: GLP-1s. These diabetes and weight loss drugs are now becoming options for clients struggling with heavy drinking. This is because emerging research has found that drugs like Ozempic don’t only suppress food cravings, many people have been able to significantly reduce their drinking on the drug, making it an interesting and safe off-label option for people with Alcohol Use Disorder.

Medication-Assisted Treatment and AUD

Typical Medication-Assisted Treatment for Alcohol Use Disorder (AUD) involves drugs meant to address addiction through neurotransmitter pathways. While not common, physicians and treatment centers do prescribe such as naltrexone and acamprosate. While available to prescribe, they don’t work for everyone and don’t have a high rate of compliance. 

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutides such as Ozempic or Mounjaro, offer an entirely new entry point by modulating the brain’s reward-seeking and cue-reactivity circuits, according to research. 

Addiction counselors frequently hear clients on GLP-1s report that their “alcohol noise”, another way to describe the persistent mental intrusion and compulsive urge to drink, simply turns down while on GLP-1s. Because GLP-1s do not yet have an FDA indication for addiction, prescribing them for AUD remains an off-label medical practice, making it essential for behavioral health professionals to understand how they fit into a client’s overall recovery plan.

When is GLP and alcohol treatment appropriate?

Because GLP-1 agonists are used off-label for addiction, medical providers evaluate candidates carefully rather than using them as an initial, routine intervention:

  • Comorbid Metabolic Conditions: Off-label prescribing is most straightforward when a client diagnosed with AUD also has type 2 diabetes or obesity. The medical provider prescribes the GLP-1 for its primary metabolic indication, allowing the client to simultaneously benefit from reduced alcohol cravings. 
  • Harm Reduction Goals: For people who struggle with binge episodes or heavy drinking days rather than immediate complete abstinence, GLP-1s appear particularly effective at blunting alcohol use on drinking days.
  • Non-Response to Standard AUD Drugs: When a client has tried FDA-approved options like naltrexone without sufficient craving relief or experienced intolerable side effects, doctors now may consider a GLP-1 as an alternative mechanism.
  • Integration with Psychotherapy: Like all tools for addiction and healthcare, GLP-1s are not standalone solutions. They are most effective alongside traditional treatment and tools such as Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), or peer recovery groups to help clients build long-term coping mechanisms while craving intensity is low. 

Medications are just one tool in the box when it comes to recovery. For many, they are vital and help put space between a person and their last alcohol use, making it easier to stay sober and focus on recovery.

How do GLP and alcohol interact in the brain?

GLP-1 receptor agonists act on the gut-brain axis, targeting central nervous system pathways that govern reward, motivation, and impulse control. Normally, drinking alcohol triggers a rapid release of dopamine in reward centers of the brain, reinforcing the compulsion to keep drinking.

Research published in Endocrinology demonstrates that GLP-1 receptors are densely distributed throughout these same mesolimbic reward regions. When a GLP-1 agonist binds to these central receptors, it blunts the alcohol-induced dopamine surge. For a person with AUD, this translates to diminished euphoric reward from drinking, reactions to known triggers (such as seeing a bar or feeling stressed), and a noticeable reduction in obsessive thoughts about alcohol.

What does clinical research show for GLP and alcohol outcomes?

Recent clinical trials and observational studies highlight several encouraging metrics for addiction professionals tracking client outcomes:

  • Fewer Heavy Drinking Days: Double-blind randomized controlled trials, such as a landmark study covered by AJMC, found that people seeking AUD help while on semaglutide experienced a significantly greater reduction in heavy drinking days and reduced total monthly alcohol intake compared to placebo.
  • Lower Alcohol-Related Hospitalization: Population-level data published in Nature Medicine and PMC show that people with AUD prescribed GLP-1s had a 28% to 36% lower risk of alcohol-related hospitalizations.
  • Reduced Biomarkers of Organ Stress: Clinical trial summaries highlighted by NIH note that GLP-1 therapy combined with CBT significantly reduced liver enzyme stress markers (such as ALT and GGT), marking concrete physical recovery alongside behavioral change.

Like all medications, there is room for error. It may not be the right tool for everyone, and some people will suffer gastrointestinal side effects that make the medication undesirable.

Treatment counselors  should coordinate with a client’s prescribing physician to monitor for side effects, mood changes, and unintended weight loss in non-obese individuals. 

There are always other tools to try for people who are trying to get sober. GLP-1’s are a promising new development that not only may help more people stay sober, but also may change our understanding of how alcohol addiction works in the brain. 

Learn More About Recovery Housing

Learn more about recovery housing, sober living, and the sober lifestyle by browsing our directory of recovery homes. SOARR helps set the standards for the industry and we’re always happy to have new members come to our networking events. Get in touch to learn more!